The SAMUKeppra study in prehospital status epilepticus: lessons for future study
- PMID: 28090524
- PMCID: PMC5220030
- DOI: 10.21037/atm.2016.11.67
The SAMUKeppra study in prehospital status epilepticus: lessons for future study
Abstract
In the Lancet Neurology article "Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial" the authors conducted a prehospital, randomized controlled study to determine which treatment is more effective for status epilepticus (SE): benzodiazepine alone, or in combination with levetiracetam (LEV). Although the study had negative results, several aspects of the trial design likely masked any added effect that LEV may have had in controlling SE, including: higher doses of benzodiazepines, lower thresholds for determining cessation of SE, and a smaller sample size. Regardless, the study reaffirms the effectiveness and importance of early and adequate benzodiazepine dosing and helps guide us in designing future studies for treatment of SE.
Keywords: SAMUKeppra; Status epilepticus (SE); clonazepam; levetiracetam (LEV); prehospital.
Conflict of interest statement
The authors have no conflicts of interest to declare.
Comment on
-
Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial.Lancet Neurol. 2016 Jan;15(1):47-55. doi: 10.1016/S1474-4422(15)00296-3. Epub 2015 Nov 28. Lancet Neurol. 2016. PMID: 26627366 Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources